# ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

> **NCT00263965** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 105 (—)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tesaglitazar
- **DRUG:** Metformin
- **BEHAVIORAL:** Dietary and lifestyle modification counseling

## Key facts

- **NCT ID:** NCT00263965
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 105 (—)
- **Why stopped:** The development program has been terminated
- **Last updated:** 2008-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00263965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00263965, "ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00263965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*